These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

70 related articles for article (PubMed ID: 6210119)

  • 1. [Fibrinolytic action of an enzyme preparation conjugated with specific antibodies].
    Torchilin VP; Maksimenko AV; Ignashenkova GV; Tishchenko EG; Ermolin GA
    Biull Eksp Biol Med; 1984 Nov; 98(11):556-8. PubMed ID: 6210119
    [TBL] [Abstract][Full Text] [Related]  

  • 2. [Fibrinolytic action of an enzyme preparation covalently bound to modified thrombin].
    Maksimenko AV; Rusetskiĭ AN; Torchilin VP
    Biull Eksp Biol Med; 1987 Jan; 103(1):35-8. PubMed ID: 3801648
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [Drug preparations of immobilized enzymes with enhanced affinity for the site of action].
    Torchilin VP; Maksimenko AV; Tishchenko EG; Papisov MI; Smirnov VN
    Antibiot Med Biotekhnol; 1986 Feb; 31(2):122-7. PubMed ID: 2421639
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Development of an in vitro fibrin clot model to evaluate fibrinolytic agents for wound care application.
    Viennet C; Laurensou C; Goydadin AC; Faivre B; Muret P; Humbert P
    J Wound Care; 2014 Feb; 23(2):66-7, 70, 72. PubMed ID: 24526082
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Comparison of the relative fibrinogenolytic, fibrinolytic and thrombolytic properties of tissue plasminogen activator and urokinase in vitro.
    Matsuo O; Rijken DC; Collen D
    Thromb Haemost; 1981 Jun; 45(3):225-9. PubMed ID: 7025339
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Molecular mechanisms of fibrinolysis and their application to fibrin-specific thrombolytic therapy.
    Collen D
    J Cell Biochem; 1987 Feb; 33(2):77-86. PubMed ID: 3553213
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Fibrin-specific thrombolytic agents.
    Collen D
    Klin Wochenschr; 1988; 66 Suppl 12():15-23. PubMed ID: 3126344
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Thrombolytic activity of terrilytin and its effect on the coagulating system of the blood].
    Andreev SV; Kubatiev AA; Iurkov VA; Kol'tsova NL
    Biull Eksp Biol Med; 1976 Aug; 82(8):936-7. PubMed ID: 1026291
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Leukofibrinolysis enhanced by leukocyte adhesion to a clot with antifibrin antibodies].
    Tsybikov NN; Kradenov AV
    Patol Fiziol Eksp Ter; 1991; (4):12-3. PubMed ID: 1798638
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Hybridization to an anti-activated platelet monoclonal antibody enhances fibrinolytic potency on urokinase.
    Du L; Yu RR; Hua ZC; Zhu DX; Wu GX; Ruan CG
    Sci China B; 1993 Dec; 36(12):1483-9. PubMed ID: 8129836
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Water-soluble modified derivatives of urokinase: fibrinolytic activity and other properties].
    Maksimenko AV; Torchilin VP
    Vopr Med Khim; 1985; 31(4):12-20. PubMed ID: 4049780
    [TBL] [Abstract][Full Text] [Related]  

  • 12. A hamster antibody to the mouse fibrinogen gamma chain inhibits platelet-fibrinogen interactions and FXIIIa-mediated fibrin cross-linking, and facilitates thrombolysis.
    Jirousková M; Smyth SS; Kudryk B; Coller BS
    Thromb Haemost; 2001 Oct; 86(4):1047-56. PubMed ID: 11686323
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Effect of soluble matrix on the stability of modified alpha-chymotrypsin].
    Molchanova NN; Kozlov LV
    Biokhimiia; 1978 Jun; 43(6):1006-11. PubMed ID: 667209
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Modification of fibrinogen by homocysteine thiolactone increases resistance to fibrinolysis: a potential mechanism of the thrombotic tendency in hyperhomocysteinemia.
    Sauls DL; Lockhart E; Warren ME; Lenkowski A; Wilhelm SE; Hoffman M
    Biochemistry; 2006 Feb; 45(8):2480-7. PubMed ID: 16489740
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Properties of chymotrypsin bound covalently to dextran.
    Zlateva TP; Krysteva M; Balajthy Z; Elödi P
    Acta Biochim Biophys Hung; 1988; 23(3-4):225-30. PubMed ID: 2470217
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Effects of drugs and parenteral solutions on vascular fibrinolytic activity.
    Johnston WE; Silver D
    Surgery; 1975 Aug; 78(2):202-10. PubMed ID: 1154264
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [The anticoagulant and fibrinolytic activity of dextran sulphate (MDS) (author's transl)].
    Matsuoka M; Jinbo C; Watanabe T; Nonura J; Sakuragawa N
    Rinsho Ketsueki; 1973 Aug; 14(8):882-90. PubMed ID: 4128641
    [No Abstract]   [Full Text] [Related]  

  • 18. ClfA(221-550), a fibrinogen-binding segment of Staphylococcus aureus clumping factor A, disrupts fibrinogen function.
    Liu CZ; Shih MH; Tsai PJ
    Thromb Haemost; 2005 Aug; 94(2):286-94. PubMed ID: 16113817
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [In vivo studies on the effect of alpha chymotrypsin on hemostasis].
    Meyer FU; Kurze D
    Stomatol DDR; 1977 Feb; 27(2):89-92. PubMed ID: 265643
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [The action of regulator peptides with different biological activities on the process of fibrin-monomer polymerization and on nonenzymatic fibrinolysis].
    Ashmarin IP; Liapina LA; Pastorova VE; Kudriashov BA
    Patol Fiziol Eksp Ter; 1991; (4):3-5. PubMed ID: 1798648
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 4.